214 related articles for article (PubMed ID: 33676766)
21. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.
Yamazaki H; Suzuki M; Otsuki A; Shimizu R; Bresnick EH; Engel JD; Yamamoto M
Cancer Cell; 2014 Apr; 25(4):415-27. PubMed ID: 24703906
[TBL] [Abstract][Full Text] [Related]
22. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
23. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
Gao J; Gurbuxani S; Zak T; Kocherginsky M; Ji P; Wehbe F; Chen Q; Chen YH; Lu X; Jennings L; Frankfurt O; Altman J; Sukhanova M
Genes Chromosomes Cancer; 2022 Feb; 61(2):71-80. PubMed ID: 34668265
[TBL] [Abstract][Full Text] [Related]
24. A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.
Cox MC; Maffei L; Buffolino S; Del Poeta G; Venditti A; Cantonetti M; Aronica G; Aquilina P; Masi M; Amadori S
Am J Clin Pathol; 1998 Jan; 109(1):24-31. PubMed ID: 9426514
[TBL] [Abstract][Full Text] [Related]
25. Clinical and Genomic Profiles of Korean Patients with
Lee J; Kim SM; Kim S; Yun J; Jeong D; Lee YE; Roh EY; Lee DS
Ann Lab Med; 2022 Sep; 42(5):590-596. PubMed ID: 35470277
[TBL] [Abstract][Full Text] [Related]
26. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
27. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis.
Yamaoka A; Suzuki M; Katayama S; Orihara D; Engel JD; Yamamoto M
Blood Adv; 2020 Apr; 4(8):1722-1736. PubMed ID: 32330245
[TBL] [Abstract][Full Text] [Related]
28. BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone.
Behrens YL; Schienke A; Davenport C; Lentes J; Tauscher M; Steinemann D; Rasche M; Knirsch S; Joachim S; Reinhardt D; Schlegelberger B; Göhring G
Cancer Genet; 2021 Jun; 254-255():70-74. PubMed ID: 33647814
[TBL] [Abstract][Full Text] [Related]
29. Two effects of GATA2 enhancer repositioning by 3q chromosomal rearrangements.
Suzuki M; Katayama S; Yamamoto M
IUBMB Life; 2020 Jan; 72(1):159-169. PubMed ID: 31820561
[TBL] [Abstract][Full Text] [Related]
30. Acute panmyelosis with myelofibrosis with EVI1 amplification.
Grygalewicz B; Woroniecka R; Pastwińska A; Rygier J; Krawczyk P; Borg K; Makuch-Łasica H; Patkowska E; Pieńkowska-Grela B
Cancer Genet; 2012 May; 205(5):255-60. PubMed ID: 22682625
[TBL] [Abstract][Full Text] [Related]
31. Activation of signaling pathways in models of t(6;9)-acute myeloid leukemia.
Chiriches C; Khan D; Wieske M; Guillen N; Rokicki M; Guy C; Wilson M; Heesom KJ; Ottmann OG; Ruthardt M
Ann Hematol; 2022 Oct; 101(10):2179-2193. PubMed ID: 35941390
[TBL] [Abstract][Full Text] [Related]
32. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
33. Molecular approaches identify a cryptic MECOM rearrangement in a child with a rapidly progressive myeloid neoplasm.
Capela de Matos RR; Othman MAK; Ferreira GM; Costa ES; Melo JB; Carreira IM; de Souza MT; Lopes BA; Emerenciano M; Land MGP; Liehr T; Ribeiro RC; Silva MLM
Cancer Genet; 2018 Feb; 221():25-30. PubMed ID: 29405993
[TBL] [Abstract][Full Text] [Related]
34. BCR-ABL1-negative acute myeloid leukaemia relapsing as BCR-ABL1-positive disease.
Bai S; Hu S
Br J Haematol; 2017 Feb; 176(4):514. PubMed ID: 27982417
[No Abstract] [Full Text] [Related]
35. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.
Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A
BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459
[TBL] [Abstract][Full Text] [Related]
36. Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice.
Cuenco GM; Ren R
Oncogene; 2004 Jan; 23(2):569-79. PubMed ID: 14724585
[TBL] [Abstract][Full Text] [Related]
37. Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation.
Chiriches C; Nicolaisen N; Wieske M; Elhaddad H; Mehmetbeyoglu E; Alvares C; Becher D; Hole P; Ottmann OG; Ruthardt M
PLoS Genet; 2022 Oct; 18(10):e1010463. PubMed ID: 36288392
[TBL] [Abstract][Full Text] [Related]
38. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
[TBL] [Abstract][Full Text] [Related]
39. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.
Pelz AF; Kröning H; Franke A; Wieacker P; Stumm M
Ann Hematol; 2002 Mar; 81(3):147-53. PubMed ID: 11904740
[TBL] [Abstract][Full Text] [Related]
40. Decitabine combined with medium-dose cytarabine in the treatment of DEK/CAN-positive acute myeloid leukemia: a case report.
Zhang X; Zhang X
Ann Palliat Med; 2021 Apr; 10(4):4955-4958. PubMed ID: 33832283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
